Cancer Nanomedicine: From Targeted Delivery to Combination Therapy

The advent of nanomedicine marks an unparalleled opportunity to advance the treatment of a variety of diseases, including cancer. The unique properties of nanoparticles, such as large surface-to volume ratio, small size, the ability to encapsulate a variety of drugs, and tunable surface chemistry, gives them many advantages over their bulk counterparts. This includes multivalent surface modification with targeting ligands, efficient navigation of the complex in vivo environment, increased intracellular trafficking, and sustained release of drug payload. These advantages make nanoparticles a mode of treatment potentially superior to conventional cancer therapies. This article highlights the most recent developments in cancer treatment using nanoparticles as drug-delivery vehicles, including promising opportunities in targeted and combination therapy.

[1]  Robert Langer,et al.  Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. , 2012, Nanomedicine.

[2]  Robert Langer,et al.  Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. , 2011, Biomaterials.

[3]  A. Sood,et al.  EphA2 as a target for ovarian cancer therapy , 2005, Expert opinion on therapeutic targets.

[4]  Dean Ho,et al.  Multimodal Nanodiamond Drug Delivery Carriers for Selective Targeting, Imaging, and Enhanced Chemotherapeutic Efficacy , 2011, Advanced materials.

[5]  Yuanjin Zhao,et al.  Biodegradable core-shell carriers for simultaneous encapsulation of synergistic actives. , 2013, Journal of the American Chemical Society.

[6]  Robert Langer,et al.  Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. , 2013, ACS nano.

[7]  Shaoyi Jiang,et al.  Poly(carboxybetaine) nanomaterials enable long circulation and prevent polymer-specific antibody production , 2014 .

[8]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[9]  Yun Yen,et al.  First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies , 2013, Investigational New Drugs.

[10]  J. Hrkach.  Docetaxel Nanoparticle with a Differentiated Pharmacological Profile Preclinical Development and Clinical Translation of a PSMA-Targeted , 2012 .

[11]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[12]  K. Gelmon,et al.  Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[13]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[14]  Robert Langer,et al.  Ultra-High Throughput Synthesis of Nanoparticles with Homogeneous Size Distribution Using a Coaxial Turbulent Jet Mixer , 2014, ACS nano.

[15]  J. Kolitz,et al.  First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Capretto,et al.  Microfluidic and lab-on-a-chip preparation routes for organic nanoparticles and vesicular systems for nanomedicine applications. , 2013, Advanced drug delivery reviews.

[17]  P. Cullis,et al.  Lipid nanoparticle delivery systems for siRNA-based therapeutics , 2013, Drug Delivery and Translational Research.

[18]  Robert Langer,et al.  Nanoparticle technologies for cancer therapy. , 2010, Handbook of experimental pharmacology.

[19]  S. Ganta,et al.  Role of integrated cancer nanomedicine in overcoming drug resistance. , 2013, Advanced drug delivery reviews.

[20]  S. Sahoo,et al.  PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. , 2011, Advanced drug delivery reviews.

[21]  Robert Langer,et al.  Microfluidic technologies for accelerating the clinical translation of nanoparticles. , 2012, Nature nanotechnology.

[22]  Robert Langer,et al.  Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug , 2013, Proceedings of the National Academy of Sciences.

[23]  T. Jacks,et al.  Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy , 2010, Proceedings of the National Academy of Sciences.

[24]  M. Hemann,et al.  Error-prone translesion synthesis mediates acquired chemoresistance , 2010, Proceedings of the National Academy of Sciences.

[25]  Chang-Soo Lee,et al.  One Step Formation of Controllable Complex Emulsions: From Functional Particles to Simultaneous Encapsulation of Hydrophilic and Hydrophobic Agents into Desired Position , 2013, Advanced materials.

[26]  V. Sanna,et al.  Targeted therapy using nanotechnology: focus on cancer , 2014, International journal of nanomedicine.

[27]  Dean Ho,et al.  Cancer Nanomedicine: From Drug Delivery to Imaging , 2013, Science Translational Medicine.

[28]  Nicholas A Peppas,et al.  A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[29]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[30]  P. Low,et al.  Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[32]  Q. Teng,et al.  Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis , 2013, PloS one.

[33]  G. Whitesides.  The origins and the future of microfluidics , 2006, Nature.

[34]  Iseult Lynch,et al.  Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[35]  Pedro M. Valencia,et al.  Targeted Polymeric Therapeutic Nanoparticles: Design, Development and Clinical Translation , 2012 .

[36]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[37]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[38]  Ronnie H. Fang,et al.  Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform , 2011, Proceedings of the National Academy of Sciences.

[39]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[40]  V. Venditto,et al.  Cancer nanomedicines: so many papers and so few drugs! , 2013, Advanced drug delivery reviews.

[41]  N. Robert,et al.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[43]  Ronald C. Chen,et al.  Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery , 2012, Proceedings of the National Academy of Sciences.

[44]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[45]  T. Lu,et al.  Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. , 2012, ACS nano.

[46]  R. Mahato,et al.  Extravasation of polymeric nanomedicines across tumor vasculature. , 2011, Advanced drug delivery reviews.

[47]  R. Müller,et al.  'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.

[48]  Manish Kohli,et al.  Nanoparticles for combination drug therapy. , 2013, ACS nano.

[49]  Jiaqiang Xu,et al.  A robust graft-to strategy to form multifunctional and stealth zwitterionic polymer-coated mesoporous silica nanoparticles. , 2014, Biomacromolecules.

[50]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Jun Wang,et al.  Surface Charge Switchable Nanoparticles Based on Zwitterionic Polymer for Enhanced Drug Delivery to Tumor , 2012, Advanced materials.

[52]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[53]  Mark E. Davis.  The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.

[54]  Hideyoshi Harashima,et al.  A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. , 2011, Advanced drug delivery reviews.

[55]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[56]  N. Svrzikapa,et al.  First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. , 2013, Cancer discovery.

[57]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[58]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[59]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[60]  Jesse V Jokerst,et al.  Nanoparticle PEGylation for imaging and therapy. , 2011, Nanomedicine.

[61]  Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. , 2011, Angewandte Chemie.

[62]  P. Couvreur,et al.  Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting , 1999 .

[63]  S. Geary,et al.  Nanoparticle Delivery Systems in Cancer Vaccines , 2011, Pharmaceutical Research.

[64]  Xue-Qing Zhang,et al.  Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. , 2012, Advanced drug delivery reviews.

[65]  Kurt E. Geckeler,et al.  Polymer nanoparticles: Preparation techniques and size-control parameters , 2011 .

[66]  F. Caruso,et al.  Targeting cancer cells: controlling the binding and internalization of antibody-functionalized capsules. , 2012, ACS nano.

[67]  Robert Langer,et al.  Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[68]  R. Spizzo,et al.  Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. , 2013, Cancer discovery.

[69]  Jan E Schnitzer,et al.  Overcoming in vivo barriers to targeted nanodelivery. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[70]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[71]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[72]  Shaoyi Jiang,et al.  Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. , 2011, Nature chemistry.

[73]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[74]  J. Waldron,et al.  Significance of Plk1 regulation by miR‐100 in human nasopharyngeal cancer , 2009, International journal of cancer.

[75]  P. Low,et al.  Tumor detection using folate receptor-targeted imaging agents , 2008, Cancer and Metastasis Reviews.

[76]  P Couvreur,et al.  Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. , 1999, Biomaterials.

[77]  D. Bazile,et al.  Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.

[78]  Anastasia Khvorova,et al.  Induction of the interferon response by siRNA is cell type- and duplex length-dependent. , 2006, RNA.

[79]  Zhishen Ge,et al.  Functional block copolymer assemblies responsive to tumor and intracellular microenvironments for site-specific drug delivery and enhanced imaging performance. , 2013, Chemical Society reviews.